$BAP

Credicorp Ltd. Stock 12‑Month Price Target Raised to $437.02, Implies 16% Upside

Analysts covering Credicorp Ltd. raised the consensus 12-month price target to $437.02 from $433.39, based on 13 estimates. Targets range from $376.15 to $480.13. Using the Aug. 13 closing price, the update implies about 16% upside. The consensus rating remains “Buy” with 10 Buys, 3 Holds, and 0 Sells.

Original reporting
Published Aug 14, 2026, 7:20 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 8:17 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Credicorp Ltd. Stock 12‑Month Price Target Raised to $437.02, Implies 16% Upside — source image
Decision brief

The 30-second read

$BAPBullishLow
01

Why it matters

A higher consensus PT and unchanged “Buy” rating can reinforce bullish positioning, but the lack of new company-specific information limits trading edge.

02

Market read

This is a sentiment/expectations update rather than a fundamental disclosure.

03

What to watch

The article does not provide the underlying thesis for the PT change, so traders should not assume improved fundamentals or revised earnings estimates.

Relevance 4/10Novelty 4/10Timing: pre-market today (published 07:20 UTC)

Background

The piece summarizes FactSet-based analyst consensus: average 12-month PT, range, and rating distribution.

Company-level read

Ticker impact

$BAPBullishMedium confidence
Context

Credicorp’s average analyst price target rose from $433.39 to $437.02, implying about 16% upside versus the Aug. 13 close.

Expected impact

Mild positive bias for the stock over days, with limited follow-through unless new company-specific fundamentals emerge.

Evidence & confidence

The article reports a consensus price-target revision and unchanged rating mix, without any new earnings, guidance, or operational disclosure.

Market effects

Limited sector read-through because the update is purely analyst PT consensus, not a sector-wide fundamental change.

Minimal, as the note does not cite Peru/LatAm macro or regulatory developments.

Low, since it is a single-company analyst target update without broader market catalysts.

Counterpoint

Price-target changes can lag fundamentals; without new earnings or guidance, the market may discount the PT update quickly.

Key entities

  • Credicorp Ltd.

    Subject of the article, with analyst consensus 12-month price target raised to $437.02.

Related articles

$BAPMedAI 8/10

Credicorp Q2 Earnings Call Highlights

Credicorp (NYSE:BAP) discussed Q2 results and outlook on an earnings call, including plans to reassess El Niño-related expected losses by late Q3 or early Q4. Management said full-year 2026 cost of risk should stay within guidance, raised 2026 loan-growth to ~12% and fee-income to high-teens, and reaffirmed 2026 ROE guidance ~19.5%. BCP ROE 29.2%, Mibanco ROE 22.9%, Yape has 16M+ MAUs.

$BAPHighAI 9/10

Bapcor Shares Upgraded, As Price Target Slashed: Value or Trap?

Jefferies upgraded Bapcor (ASX: BAP) to Buy from Hold but cut its price target from A$1.05 to A$0.65. The stock has fallen about 75% over six months and is near A$0.38. Bapcor also secured temporary relief on its net leverage covenant, raising it to 3.5x adjusted EBITDA for test dates through 2026.

$AZNMed

13 clinical candidates revealed in Chicago

At the American Chemical Society Fall 2026 meeting, 13 new drug candidates were unveiled by various companies, targeting diseases like cancer, lupus, and acne. Presenters included Quanta Therapeutics, AstraZeneca, Novartis, and Pfizer, among others, discussing their drug discovery strategies and clinical trials.

$SLBMed

SLB (SLB) Stock News & Articles

Schlumberger (SLB) gained access to Venezuela's oilfield data and may reactivate up to 15 rigs. The company collaborates with Nvidia (NVDA) and focuses on energy sector innovation. Venezuela's payment history raises investor concerns.

$FLUTMed

Stifel: Flutter Promo Spending Could Pay Dividends for Investors

Flutter Entertainment (FLUT) shares fell 8% in a month due to planned $385M spending on promotions. Stifel analyst Jeffrey Stantial rates FLUT 'buy' with a $133 price target, citing past successful marketing strategies and potential catalysts like FanDuel market share stabilization. FLUT is down 54% YTD, trading below DraftKings (DKNG) and in-line with Entain.